Mineralys Therapeutics (MLYS) CMO exercises options, sells 2,170 shares under plan

Q: What did MLYS Chief Medical Officer David Malcom Rodman report in this Form 4?

He exercised 2,170 stock options at $16.00 per share and sold 2,170 Common shares at $27.09 per share on August 10, 2026, under a Rule 10b5-1 plan.

Q: How many Mineralys Therapeutics (MLYS) options does the CMO hold after this transaction?

After the reported option exercise, he held 13,024 stock options directly. This figure reflects the total stock options reported as outstanding following the derivative transaction in the Form 4.

Q: What prices were involved in the MLYS CMO’s August 10, 2026 transactions?

The stock options were exercised at an exercise price of $16.00 per share, and the resulting 2,170 Common shares were sold at a sale price of $27.09 per share on the same date.

Q: What type of derivative security did the MLYS CMO exercise?

He exercised a Stock Option for 2,170 shares of Common Stock , described as an exercise or conversion of derivative security with an expiration date of February 9, 2033, and a $16.00 exercise price.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Mineralys Therapeutics Chief Medical Officer David Malcom Rodman exercised 2,170 stock options for Common Stock at an exercise price of $16.00 per share on August 10, 2026, then sold 2,170 Common shares at $27.09 per share. The option exercise and related sale were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Following the transaction, he held 13,024 stock options directly.

Insider Trade Summary 10b5-1

Exercise and Sale: 2,170 shares ($24K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Rodman David Malcom

Role Chief Medical Officer

Sold 2,170 shs ($59K)

Approx. gross sale proceeds $59K

Approx. exercise cost $35K

Approx. pre-tax spread $24K

Type	Security	Shares	Price	Value
Exercise	Stock Option ^{F1, F2}	2,170	$0.00	$0.00
Exercise	Common Stock ^F1	2,170	$16.00	$35K
Sale	Common Stock ^F1	2,170	$27.09	$59K

Holdings After Transaction: Stock Option — 13,024 shares (Direct); Common Stock — 51,384 shares (Direct)

Footnotes (2)

F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
F2. The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter.

Key Figures

Options exercised: 2,170 shares Exercise price: $16.00 per share Shares sold: 2,170 shares +4 more

7 metrics

Options exercised 2,170 shares Stock Option for Common Stock exercised on August 10, 2026

Exercise price $16.00 per share Exercise or conversion price of Stock Option

Shares sold 2,170 shares Common Stock sale on August 10, 2026

Sale price $27.09 per share Price for Common Stock sale transaction

Options held after transaction 13,024 options Total Stock Options following derivative transaction

Option expiration date February 9, 2033 Expiration date of the Stock Option exercised

10b5-1 plan adoption date October 6, 2025 Date the Rule 10b5-1 trading plan was adopted

Key Terms

Rule 10b5-1 trading plan, Stock Option, exercise or conversion of derivative security, Common Stock

4 terms

Rule 10b5-1 trading plan financial

"These transactions were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option financial

"The stock option vests as to 25% of the total number of shares"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

Common Stock financial

"shares of Common Stock subject to the option on each monthly anniversary"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/12/2026 - 07:33 PM Accepted by SEC EDGAR 08/12/2026 - 07:33 PM

FAQ

What did MLYS Chief Medical Officer David Malcom Rodman report in this Form 4?

He exercised 2,170 stock options at $16.00 per share and sold 2,170 Common shares at $27.09 per share on August 10, 2026, under a Rule 10b5-1 plan.

How many Mineralys Therapeutics (MLYS) options does the CMO hold after this transaction?

After the reported option exercise, he held 13,024 stock options directly. This figure reflects the total stock options reported as outstanding following the derivative transaction in the Form 4.

What prices were involved in the MLYS CMO’s August 10, 2026 transactions?

The stock options were exercised at an exercise price of $16.00 per share, and the resulting 2,170 Common shares were sold at a sale price of $27.09 per share on the same date.

Were the MLYS CMO’s trades made under a Rule 10b5-1 trading plan?

Yes. The Form 4 states the transactions were effected pursuant to a Rule 10b5-1 trading plan that was adopted on October 6, 2025, indicating they followed a pre-arranged schedule.

What type of derivative security did the MLYS CMO exercise?

He exercised a Stock Option for 2,170 shares of Common Stock, described as an exercise or conversion of derivative security with an expiration date of February 9, 2033, and a $16.00 exercise price.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rodman David Malcom

(Last)

(First)

(Middle)

150 N. RADNOR CHESTER ROAD

SUITE F200

(Street)

RADNOR

PENNSYLVANIA

19087

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/10/2026		M⁽¹⁾		2,170	A	$16	53,554	D
Common Stock	08/10/2026		S⁽¹⁾		2,170	D	$27.09	51,384	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option	$16	08/10/2026		M⁽¹⁾			2,170	⁽²⁾	02/09/2033	Common Stock	2,170	$0	13,024	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

2. The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter.

Remarks:

	/s/ Adam Levy, Attorney-in-fact	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR